🦋 #EULAR2026: New Insights into #SLE Therapy (Bertsias) Withdraw GC first in sustained remission; consider IS/biologic withdrawal after ≥3 yrs. Safest GC withdrawal when 3 factors combine: slow taper (6m) + good HCQ adherence + remission (DORIS/LLDAS) @ElvisHysa

#EULAR2026: Treating PH in CTD (Allanore) Novel disease-modifying drug → sotatercept (TGF-β/activin pathway), can reverse pulmonary vascular remodeling. Unlike idiopathic #PAH, CTD-PAH has an autoimmune component → treat the disease + the pulmonary vasculature. @ElvisHysa

Periostin-expressing fibroblasts: another kid on the blicknof RA synovium and PsA skin involvement? Wonderful presentation by @carolineospelt #EULAR2026 @javierrcarrio

#EULAR2026 debate: To (Re)biopsy or Not in ANCA-Associated Vasculitis? ⚖️ Jayne (Pro): biopsy stays guideline-recommended: diagnosis, prognosis & drug selection ⚖️ Tomelleri (Contra): renal biopsy may be replaced by biomarkers (usCD163, uMCP-1, uEGF) and imaging @ElvisHysa

Platelets as leading drivers of immune processes in autoimmunity @m_scherlinger ➡️ fuel inflammation ➡️promote organ damage ➡️potential therapeutic target Very interesting and well attended session! @javierrcarrio

🧬 #EULAR2026 Systemic Sclerosis, by Oliver Distler Cell-based & T-cell engaging therapies enter refractory SSc: 🔹 CAR-T: median pFVC +6.4% at 6m (BREAKFREE-1) 🔹 BCMA-TCE teclistamab: ↓mRSS & tendon friction rubs (Nat Med 2026) Beyond conventional IS. #SSc @ElvisHysa

#EULAR2026: GCA & Takayasu, Shared Pathways, Different Ages? Two prototypes, one spectrum. TAK: CD8+ cytotoxic injury, prominent fibrosis GCA: macrophage-driven, self-renewing lesions Shared IL-6/JAK response; TNFi only in TAK from Weyand, Tomelleri, Direskeneli @ElvisHysa

#EULAR2026 Prof. Della Torre When to suspect #IgG4RD: tumefactive/stenosing lesions AFTER excluding malignancies & infections. Serum IgG4 are NOT diagnostic: interpret in context. FDG-PET helps map disease burden. Histology remains the mainstay. @ElvisHysa

Loreto Carmona @Inmusc1 guide us through the implementation strategy Very practical tips from @eular_org recommendations and #educAr initiative CFIR-ERIC marching tool and StrategEase tool provide valuable tools @javierrcarrio

Which implementation model should I choose? ➡️Dr. Schiphof introduces the whole implementation process and decision-making. ➡️Useful examples from @eular_org OA recommendations ➡️ Combination is optimal @javierrcarrio

#HOTsession #EULAR2026: Treatment of ICI-induced rheumatic #irAEs by Prof Koops Key points: ✅ From mild to life-threatening ✅ Treat early, don't await the full diagnostic picture ✅ Control symptoms while supporting cancer therapy ✅ Collaboration with oncologist @ElvisHysa

Some of the faces behind the posts! Regular and guest social media editors of @eular_ARD and @eular_ero catching up at #EULAR2026 @epirheum @RafaPrieto4 @ElvisHysa @dr_emrebilgin @Nellziade @RubenDFernandes @Ertugrul_cagri @daliyapencheva @javierrcarrio @alessia_alunno

#EULAR2026 congress is starting tomorrow and we are thrilled to introduce this year’s guest social media editors. Make sure you follow also ARD sister journal @eular_ero for live updates! #rheumedu

EULAR highlights🔵 ➡️long-term follow up data from the ARIAA study: 6months treatment intervention w Abatacept delays progression to RA for up to 4 years in ACPA+ patients w artralgia! #EULA25 @BurjaBlaz

👋🏼We say goodbye to the #EULAR2025 Congress with the Highlights session, summarising all the amazing work of this edition. ⏭️ Looking forward to seeing you in London for the #EULAR2026. @RafaPrieto4

Great session yesterday on #DISH with a talk from @Nellziade. Even Ramses might have had it! It was very insightful also to learn about the role of comirbidities, especially #diabetes! #EULAR2025 Posted by @msokolova_rheum

💉Digital ulcers in SSc ➡️selexipag (prostacyclin receptor agonist) showed superior results in treating DU in SSc as compared to iloprost ➡️off-label use in retrospective multicentre italian study ➡️further trials needed to confirm promising results #EULAR2025 @BurjaBlaz

A rarely discussed topic of #rheumatoid vasculitis - a great talk from Dr. Makol from the @MayoClinic at #EULAR2025 ⭐️still very high mortality! ⭐️suspect in smn with constitutional symptoms, low complement (C3!) and ⬆️APR ⭐️RTX emerging as a treatment option By @msokolova_rheum

❓How to improve adherence during the transition from paediatric to adult care? 🔝A great session including in the same session the voice of patients, HPRs and rheumatologists, supported by @FerEstevezLopez and Loreto Carmona as chairs. #EULAR2025 @RafaPrieto4

#EULAR2025 WIN in large vessel vasculitis. ⚠️up to 30% #PMR patients have subclinical #GCA which is associated with: ⚠️older age ⬆️ morning stiffness ⬆️hip involvement If you start with ⬇️ than 20 mg pred in subclin. GCA-> 100% relapse risk! Posted by @msokolova_rheum